Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_assertion type Assertion NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_head.
- NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_assertion description "[Although clinical trials have been performed with anti IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic niche in primary eosinophilic diseases and HES have yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_provenance.
- NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_assertion evidence source_evidence_literature NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_provenance.
- NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_assertion SIO_000772 21761433 NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_provenance.
- NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_assertion wasDerivedFrom befree-2016 NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_provenance.
- NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_assertion wasGeneratedBy ECO_0000203 NP910029.RAon0Qu9UZg2AnoBg8eQ7tyLtaDyIJ5ZRkLGPBJA3vYYE130_provenance.